Background-Given the lack of promptness and inevitable use of additional contrast agents, the myocardial viability imaging procedures have not been used widely for determining the need to performing revascularization.
Introduction
A dysfunctional myocardium can be characterized by 3 separate entities: stunning, hibernation, and scar. 1, 2 Within this spectrum, the differentiation of scar from stunning or from hibernation is essential for future prognosis, as stunning and hibernating myocardium are considered reversible with appropriate revascularization treatment. [3] [4] [5] Various imaging modalities including stress echocardiography, single-photon emission CT, positron emission tomography, and magnetic resonance imaging (MRI) have been used to discriminate viable and nonviable myocardium. 6, 7 Of these modalities, delayed hyperenhancement (DHE) imaging using MRI has been proven to be the most reliable in the detection of myocardial scar. [8] [9] [10] [11] Given iodine-based contrast has similar kinetics to that based on gadolinium, 12 there has been some attempt in using multislice CT (MSCT) for DHE imaging. 13, 14 Furthermore, MSCT has demonstrated excellent correlation with DHE of MRI and histopathologic specimens. 15 However, viability imaging of the myocardium has not been used extensively for determining the need to perform revascularization-primarily because viability imaging including MSCT cannot be performed simultaneously alongside invasive coronary angiography (ICA). As such, patients typically undergo coronary revascularization as a secondary procedure several days after undergoing viability imaging, which can be time-consuming and impractical, and the patient may also be prone to potential side effects from the use of additional intravenous contrast agents. 16 Recently, Sato et al demonstrated that myocardial viability imaging using DHE by MSCT could be obtained immediately after percutaneous coronary intervention (PCI) without additional use of intravenous contrast. 17 A drawback of that study, however, was that patients' cardiac MSCT scans were performed after coronary revascularization; hence, these study findings are not applicable for determining coronary revascularization. Nevertheless, these observations imply that DHE imaging by MSCT after ICA without additional contrast use may be useful in overcoming some of the current limitations surrounding viability imaging. In this investigation, we therefore studied the feasibility of myocardial viability assessment, concurrent with diagnostic ICA, for the guidance of coronary revascularization using a novel hybrid system comprising ICA and MSCT.
Materials and methods

Animal model preparation
The study complied with the regulations of the animal care committee of the Cardiovascular Product Evaluation Center, Yonsei University, and the National Institutes of Health publication of "The 1996 Guide for the Care and Use of Laboratory Animals." 18 In all, 14 Yucatan miniature swine models (female; age, 3 months; weight, 28-30 kg) were enrolled for the present study. The pigs were initially sedated with tiletamine and zolazepam (Zoletil 50; Virbac, Carros, France) 5 mg/kg and xylazine (Rompun; Bayer Korea, Seoul, South Korea) 2 mg/kg and then intubated. Anesthesia was maintained with 1% to 1.5% isoflurane in 100% oxygen gas at a flow of 1.5 mL/minute and administered by the anesthesia machine with mechanical ventilation (Primus; Drager, Lubeck, Germany). Adequate anesthesia was confirmed by the absence of a limb withdrawal reflex. Monitoring by limb-lead electrocardiography (ECG) was performed throughout the operation with polygraph. Before procedures, ketorolac (5 mg/kg) was administered intramuscularly to relieve pain and prevent inflammation. This protocol was used for the creation of myocardial infarction, ICA, and MSCT image acquisitions.
Creation of myocardial infarction
The experimental swine model was placed in a dorsal recumbency, and the incision site was prepared aseptically with standard Betadine (Betadine, Korea Pharma, Seoul, Korea) and alcohol scrub. Fifteen minutes before balloon occlusion, all swine received 300-mg amiodarone to lower the risk of ventricular fibrillation. After placement of a 6F introducer sheath in the right carotid artery by surgical cut down, each animal received a single dose of heparin (200 U/kg) and bretylium tosylate (2.5 mg/kg). Under fluoroscopic guidance (INFX-8000V; Toshiba), a 6F Judkins left guiding catheter (Cordis; Johnson and Johnson) was positioned in the left coronary ostium. After the intracoronary administration of nitroglycerin (200 μg), coronary angiography was determined by cine-radiography to demonstrate left anterior descending (LAD) artery patency (Fig. 1) . A 3.0 × 15-mm angioplasty balloon (Medtronic) was then positioned immediately distal to the first diagonal LAD vessel and inflated to normal pressure, which was dependent on its compliance chart to achieve vessel occlusion for a period of 90 minutes, followed by reperfusion. Animals were monitored until full recovery and then were returned to housing.
Imaging data acquisition for MSCT after conventional ICA
Two weeks after inducing myocardial infarction, ICA and MSCT were performed. Swine were anesthetized as described previously. Coronary angiography and acquisition of MSCT viability imaging were performed using a novel cardiovascular interventional therapeutic CT (CVIT-CT) system, which allowed for the acquisition of coronary angiography and MSCT consecutively (Fig. 2) . Before ICA procedures, a noncontrast MSCT image was obtained for the purpose of acting as a control. For ICA procedures, a CVIT-CT system was set to coronary angiography mode. To mimic clinical ICA procedures, routine coronary angiography images for the left coronary artery were obtained in right anterior oblique caudal, right anterior oblique cranial, anterior-posterior cranial, left anterior oblique cranial, and left anterior oblique caudal views, as well as anterior-posterior caudal. A total of 24 mL (4 mL per each view) contrast agent (Iomeron 400 mg/mL; Bracco, Milan, Italy) was injected intracoronary during routine ICA. After obtaining the ICA images, the CVIT-CT system was switched to MSCT acquisition mode. MSCT images were acquired using a prospective ECG-gated 320-channel scanner (Aquilion ONE; Toshiba Medical Systems, Otawara, Japan) with the following characteristics: collimation and slice thickness, 0.5 mm; reconstruction increment, 0.3 mm; reconstruction field of view, 109 to 123 mm; reconstruction kernel, FC43; reconstruction algorithm, adaptive iterative dose reduction 3D; tube rotation time, 0.35 seconds; tube voltage, 120 kVp; current, 550 mA; and prospective ECG gating, 75% R-R interval. We assessed intracoronary-injected contrast agent kinetics by tracking signal intensity of the infarct region and remote myocardial region (adjacent left ventricular free wall and mid-ventricular septum) over a duration of 20 minutes. To explore the contrast wash-in and wash-out kinetics and determine optimal image acquisition timing for DHE after intracoronary contrast injection by time delay between contrast injection and MSCT image acquisition, all MSCT scans were performed at 2, 5, 7, 10, 15, and 20 minutes after last intracoronary contrast injection, and each image was compared with histopathologic specimens. Reconstructed images were then transferred to a commercially available workstation (Vitrea fX 6.4; Toshiba Medical Systems, Otawara, Japan) for subsequent analyses.
Histopathologic specimen preparation and interpretation
The heart was removed immediately after image acquisition for sectioning and staining. The heart was sliced in 10-mm consecutive sections in the short-axis plane. To obtain a viability staining, sliced myocardia were embedded in 1% of 2, 3, 5-triphenyltetrazolium chloride (TTC) solution (Sigma-Aldrich; St. Louis, MO) at 37° C for 15 minutes, followed by fixation in a buffered 4.5% formalin solution for 20 minutes. For histopathologic specimen analysis, all slices showing myocardial scar by TTC staining were digitally photographed for further investigation. Infarct size was defined as TTC-negative area by hand planimetry for each myocardial slice and expressed as an area ratio (%) for each section using ImageJ platform (ImageJ version 1.36b; National Institutes of Health, Bethesda, MD). The area of myocardial infarction of the histopathologic specimen was measured independently from MSCT images.
Image data analysis
For MSCT image analyses, multiplanar reconstructions of axial slices were coregistered using anatomic landmarks by an independent investigator who did not further participate in MSCT analysis (Fig. 3) . 13, [19] [20] [21] Thereafter, 2 experienced readers, who were level III equivalent and/or board certified in cardiovascular CT, 22 were blinded to histopathologic specimen results, analyzed the MSCT images. To quantify infarct size in each matched short-axis slice, the endocardial and epicardial contours of the left ventricle and the contours of the delayed enhancement were manually measured repeatedly. Mean values from those measurements were used for further calculations. The presence of an infarct size in an MSCT image was defined as the delayed enhancement area for each matched short-axis slice and expressed as a percentage of the area of the total left ventricular wall at each slice. The percentage difference in infarct size by MSCT compared with histopathologic specimen at each time point was defined as the difference between the infarct size in MSCT and histopathologic specimen divided by the infarct size by a histopathologic specimen.
Statistical methods
For the MSCT images, the interobserver reliability in the measurement of the infarct size was assessed by means of the intraclass correlation coefficient (2-way random, single measure). 23 The CT attenuation differences between infarct tissue and remote normal myocardium at each time point were compared using paired t test. The infarct size measurement errors of MSCT over time were compared using repeated measures 1-way analysis of variance with Bonferroni correction for post hoc analyses. The agreement and correlation between infarct size assessed with MSCT and histopathology were evaluated with Bland-Altman analysis and the Pearson correlation coefficient, respectively. All tests were 2-sided, and P < .05 was regarded as statistically significant. Statistical analyses were performed using SAS (version 9.2; SAS Institute Inc., Cary, NC).
Results
Among 14 swine models, 2 pigs expired because of persistent ventricular fibrillation during the creation of a myocardial infarction. Thus, multidetector CT images and histopathologic images were obtained in a total of 12 pigs.
Optimal image acquisition timing for DE imaging after CAG
As illustrated in Fig. 4 , myocardial delayed scan images were obtained serially at 2, 5, 7, 10, 15, and 20 minutes. MSCT identified a peak CT attenuation of the infarct area (222.5 ± 36.5 HU) and normal myocardium (116.1 ± 45 HU; Fig. 3A and B) , with a maximum mean difference in CT attenuation between the infarct areas and normal myocardium of 106.4 at 2 minutes after contrast injection (P for difference = 0.002). Contrasts were subsequently washed out and the attenuation difference between infarct and normal myocardium was decreased to 65.7 ± 23.6 HU at 5 minutes (P for difference compared with normal myocardium = 0.003). The statistical significance of differences in CT attenuation between infarct area and remote normal myocardium was observed up until 15 minutes after the last intracoronary contrast injection.
We calculated the percentage difference in infarct size by MSCT compared with histopathologic specimen at each time point between 2 and 20 minutes to investigate the accuracy of MSCT infarct measures over time (Fig. 5 ). Mean percentage difference in infarct size by MSCT appeared to increase with time from the last intracoronary contrast injection to the MSCT image acquisition (P = .035, repeated measurement analysis of variance). Compared with the mean percentage difference at 2 minutes (8.5% ± 1.8%), the mean percentage difference at 5 minutes (9.5% ± 1.9%) did not differ materially (P = .580). However, the mean percentage differences vs histopathologic specimen increased significantly from 7, 10, 15, and 20 minutes (eg, 24.1% ± 8.2%, 30.0% ± 13.3%, 25.2% ± 17.4%, and 59.9% ± 12.7%, respectively) when compared with 2-minute postintracoronary contrast injection (all P < .05).
Comparison of the size of hyperenhanced regions on MSCT and TTC-stained area of histopathologic specimen
On the basis of the previously mentioned study findings and also considering the feasibility in the clinical setting to allow transition time from ICA to MSCT acquisition, we used the infarct measurement result at 5 minutes to test for further agreement between MSCT and histopathologic specimens. Interobserver variability for identification of infarct size between 2 experienced readers for MSCT images was intraclass correlation coefficient = 0.93 (95% confidence interval, 0.87-0.97). Direct comparisons of reconstructed slice-matched DHE area measured by MSCT after ICA demonstrated excellent correlation with TTC-derived infarct size in histopathologic specimens (r = 0.952; 95% confidence interval, 0.904-0.976; P < .001; Fig. 6A ). Finally, Bland-Altman plots of the difference between DHE by MSCT and TTC-derived infarct measurements plotted against their means (Fig. 6B ) demonstrated good agreement between the 2 methods.
Discussion
In this experimental study involving swine models, we set out to determine the feasibility of myocardial viability assessment by ascertainment of delayed-enhancement MSCT after conventional ICA without additional contrast agent use. The major finding was that myocardial viability assessment using DHE area measured by MSCT between 2-and 5-minute duration after conventional ICA displayed excellent agreement with infarct size as measured by histochemical staining.
The importance of a viability assessment using various imaging modalities for determination of revascularization treatment is well documented. 24, 25 Given the available data, current guidelines suggest viability evaluation in patients with left ventricular dysfunction and who are known to be amenable to revascularization is appropriate. 26 As a surprise, however, viability imaging has not been widely used in the clinical setting. One plausible explanation for its lack of use in the clinical setting to date is that it has remained a challenge to conduct viability imaging simultaneously with ICA. Current procedures after diagnosis of obstructive coronary artery disease by ICA indicate patients should undergo the following costly and time-consuming steps: (1) being discharged from the catheterization laboratory; (2) waiting for scheduling a viability imaging test; (3) undergoing a viability test; (4) waiting for the viability imaging results; and (5) if necessary, revisiting the catheterization laboratory to undergo a secondary revascularization procedure. Furthermore, another reason that could influence the physicians' decision to use viability imaging for determining revascularization is the additional use of contrast agent required. Indeed, contrast agents required to perform an MSCT or MRI could expose the patient to potential risks including nephrotoxicity or nephrogenic systemic fibrosis. 16 Although it bears mentioning, these potential side effects are more common in patients with renal dysfunction, which is prevalent in patients who are referred for viability imaging. 27 Foremost, the present study demonstrates that viability assessment using a novel hybrid CVIT-CT system can likely overcome these limitations. On background of present study data, the CVIT-CT system permitted accurate viability assessment without additional contrast agent administration almost concurrent with ICA. Importantly, optimal viability images were obtained after 2 to 5 minutes after the final intracoronary injection of contrast agent for conventional ICA, which is fitting with prior intravenous injection viability studies. 28 Conversely, the accuracy of viability assessment after intracoronary injection diminished after 7 minutes, demonstrating that the wash-out of contrast occurred at a more rapid rate than that observed under intravenous injection. [28] [29] [30] Hence, quick acquisition (ie, approximately 5 minutes duration) of DHE imaging by MSCT is an important component for the accurate assessment of myocardial viability, especially when using the method described in the present study.
Moving forward, we suggested the conceptual framework (Fig. 7) that provides a stepwise, timed approach for image acquisition and interpretation process in patients with suspected coronary artery disease and severe left ventricular dysfunction. If the patient has a coronary artery disease on ICA, the CVIT-CT system is immediately switched to MSCT acquisition mode and performs a viability scan within 5 minutes. An experienced radiologist or cardiologist will interpret the viability scan immediately after the scan and discuss with the interventionalist to perform revascularization based on the integrated information of ICA and viability imaging. This whole process can be completed within 20 minutes, and coronary revascularization can be performed immediately, eliminating, in part, any unnecessary time delay between ICA and intervention and the potential hazard from additional contrast agent use of MSCT or cardiac MRI. Forthcoming studies are needed to fully address the clinical utility, safety, and efficacy of this novel protocol.
Limitations
The present study only included subacute (2 weeks) experimentally produced infarcts in swine models. Thus, the feasibility of the current imaging acquisition protocol in an emergency coronary intervention or chronic myocardial infarction setting (ie, >2 weeks) remains to be determined. In addition, the present study was performed using reopened arteries at the time of contrast injection and MSCT image acquisition. In the clinical myocardial infarction setting, the artery may be closed at the time of contrast injection, and the enhancement quality and timing may differ. Forthcoming studies aimed at exploring the contrast kinetics and delayed-enhancement qualities in obstructed arteries appear necessary. Finally, given the design and nature of the present study protocol, myocardial viability imaging could not be acquired between 0 and 2 minutes after administration of the contrast agent. Additional studies investigating the wash-in and wash-out kinetics of intracoronary contrast administration are required.
Conclusion
In the current investigation, the feasibility of myocardial viability assessment by DHE using MSCT after conventional ICA was proven in an experimental swine model. Forthcoming studies are now warranted to address the safety, utility, and validity of concurrent ICA and MSCT within the clinical setting. Representative invasive coronary angiography images acquired before, during, and after balloon injury (white arrow) for creation of myocardial infarction. Schematic illustration (A) and actual image (B) of a novel cardiovascular interventional therapeutic CT system for a consecutive acquisition of invasive coronary angiography and myocardial viability imaging by multislice CT. Examples of comparisons of histopathologic specimens and multislice CT images on the 4 swine models (A-D). The black and white arrows indicate TTC-stained area on histopathologic specimen and hyperenhanced regions on MSCT respectively. The percentage difference in infarct size by multislice CT (MSCT) compared with histopathologic specimen at each time point after intracoronary contrast injection for conventional invasive coronary angiography. The correlation (A) and Bland-Altman analyses (B) of infarct sizes assessed by histopathologic specimen and multislice CT (MSCT). Conceptual framework of viability assessment using a cardiovascular interventional therapeutic CT system in a patient with suspected coronary artery disease and severe left ventricular dysfunction. ICA, invasive coronary angiography.
